Stocks Health care NRXP
NASDAQ · Health careNRX Pharmaceuticals, Inc. (NRXP)
NRX Pharmaceuticals, Inc. brought in $3.6M of revenue over the twelve months to June 30, 2026. It posted a net loss of $23.5M. At June 30, 2026 it held $26.7M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.
Key facts about NRX Pharmaceuticals, Inc.
- Net worth
- NRX Pharmaceuticals, Inc. has a market value (market cap) of $102.2M at the latest share price, and shareholders' equity of -$170K on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $1.4M, with a net loss of $28.6M. Over the 12 months to June 30, 2026: revenue $3.6M, net loss $23.5M.
- Cash flow
- In fiscal 2025 operations used $14.1M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 14, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- NRX Pharmaceuticals, Inc.'s next report is expected around November 13, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What NRX Pharmaceuticals, Inc. does
NRX Pharmaceuticals, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker NRXP.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $1.4M | -$28.6M | -$1.34 | n/a |
| 2024 | $0 | -$25.1M | -$2.36 | -$10.6M |
| 2023 | $0 | -$30.2M | -$3.98 | -$21.7M |
| 2022 | n/a | -$39.8M | -$0.60 | -$39.8M |
| 2021 | n/a | -$93.1M | -$1.98 | -$37.7M |
| 2020 | n/a | -$51.8M | -$1.51 | -$2.3M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where NRXP ranks in Health care
Latest SEC filings
What NRX Pharmaceuticals, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 5, 2026Additional proxy material DEFA14A
- November 5, 2026Proxy statement DEF 14A
- November 2, 2026
- October 16, 2026Other event 8-K
- October 5, 2026Material agreement8-KNRx Pharmaceuticals subsidiary was awarded a prime contract of up to approximately $11.2 million from DARPA.
- September 16, 2026Other event 8-K
- September 14, 2026
- August 17, 2026
- August 14, 2026
- August 7, 2026
Insider trades
What the people running NRX Pharmaceuticals, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
Who owns NRXP
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| The B Group, Inc.13G, passive with 2 related filers | 12.62% | August 21, 2025 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 47 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| B Group, Inc. | 4,091,767 | +1,091,767 |
| Vanguard Capital Management LLC | 1,618,159 | +457,975 |
| Ameriprise Financial Inc | 928,728 | new |
| Balyasny Asset Management L.P. | 893,864 | new |
| Citadel Advisors LLC | 680,043 | new |
| AdvisorShares Investments LLC | 659,018 | +238,551 |
| Commonwealth Equity Services, LLC | 454,418 | +56,987 |
| UBS Group AG | 423,115 | +397,888 |
| Geode Capital Management, LLC | 314,659 | +4,547 |
| BlackRock, Inc. | 220,460 | +121,465 |
| Marshall Wace, Llp | 194,580 | new |
| Vanguard Fiduciary Trust Co | 182,718 | +13,138 |
| Jane Street Group, LLC | 119,018 | +74,866 |
| Bleakley Financial Group, LLC | 117,216 | +12 |
| State Street Corp | 116,084 | +29,100 |
| Northern Trust Corp | 62,951 | +19,482 |
| Chicago Partners Investment Group LLC | 46,388 | +11,909 |
| Quadrature Capital Ltd | 43,605 | new |
| One Wealth Management Investment & Advisory Services, LLC | 43,309 | 0 |
| Morgan Stanley | 40,901 | +30,873 |
Insiders
Questions about NRXP
What does NRX Pharmaceuticals, Inc. do?
NRX Pharmaceuticals, Inc. is a company in the Health care sector, listed on NASDAQ as NRXP. Its shares trade on NASDAQ under the ticker NRXP.
What is NRX Pharmaceuticals, Inc.'s net worth?
NRX Pharmaceuticals, Inc. has a market value (market cap) of $102.2M at the latest share price, and shareholders' equity of -$170K on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is NRX Pharmaceuticals, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $23.5M on revenue of $3.6M.
How much revenue does NRX Pharmaceuticals, Inc. make?
Over the twelve months to June 30, 2026 NRX Pharmaceuticals, Inc. reported revenue of $3.6M.
When did NRX Pharmaceuticals, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the additional proxy material from November 5, 2026.
When is NRX Pharmaceuticals, Inc.'s next earnings report?
NRX Pharmaceuticals, Inc.'s next report is expected around November 13, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare NRXP with
Follow NRXP
Get an email when NRX Pharmaceuticals, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values NRX Pharmaceuticals, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.